The continuing UK ban on cannabis-based painkillers is absurd and inhumane | Simon Jenkins

Politicians running scared of big pharma and the taboo around cannabis are blocking access to these vital drugsThat the government will allow a few serious epilepsy and multiple sclerosis sufferers to getcannabidiol medicine to relieve their symptoms is good news. That is all that can be said. Once more a decision emerges from the caverns of Britain ’s NHS that reveals the evils of a politicised, centralised, deadened health service.Related:Legalisation of cannabis in the UK would help protect its users from harm | James NichollsContinue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cannabis Drugs Society NHS Health Epilepsy UK news Science Pharmaceuticals industry Business David Nutt Source Type: news

Related Links:

Telemedicine is the provision of health care services to a patient separated from the physician by a distance, with the help of information technologies and telecommunication[1]. In recent years, there is quick advancement of scope and usage of telemedicine in the field of neurology, also referred to as teleneurology. Beginning with acute stroke care, it is fast expanding to the care of persons with multiple sclerosis, Parkinson ’s disease, and epilepsy[2–6]. The two key factors driving the ever-increasing demand for telemedicine in Neurology are limited access to specialists (Neurologists) and difficulties fac...
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research
Publication date: November 2020Source: Multiple Sclerosis and Related Disorders, Volume 46Author(s): Farnaz Nikbakht, Ali Mohammadkhanizadeh, Ekram Mohammadi
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
If you ask health care providers about the most challenging condition to treat, chronic pain is mentioned frequently. By its nature, chronic pain is a complex and multidimensional experience. Pain perception is affected by our unique biology, our mood, our social environment, and past experiences. If you or a loved one is suffering from chronic pain, you already know the heavy burden. People are looking for novel, nonaddictive ways to treat pain Given the ongoing challenges of chronic pain management coupled with the consequences of the opioid epidemic, pain management practitioners and their patients are searching for eff...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Back Pain Marijuana Pain Management Source Type: blogs
Recent advances in artificial intelligence (AI) and deep learning (DL) hold promise to augment neuroimaging diagnosis for patients with brain tumors and stroke. Here, the authors review the diverse landscape of emerging neuroimaging applications of AI, including workflow optimization, lesion segmentation, and precision education. Given the many modalities used in diagnosing neurologic diseases, AI may be deployed to integrate across modalities (MR imaging, computed tomography, PET, electroencephalography, clinical and laboratory findings), facilitate crosstalk among specialists, and potentially improve diagnosis in patient...
Source: Neuroimaging Clinics - Category: Radiology Authors: Source Type: research
This article hopes to create an overview of current research on cannabinoids and the ECS, detail the potential advantages and pitfalls of their use in GI diseases, and explore possible future developments in this field.
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: CLINICAL REVIEWS Source Type: research
itin Mantri Cannabis is an annual plant with a long history of use as food, feed, fiber, oil, medicine, and narcotics. Despite realizing its true value, it has not yet found its true place. Cannabis has had a long history with many ups and downs, and now it is our turn to promote it. Cannabis contains approximately 600 identified and many yet unidentified potentially useful compounds. Cannabinoids, phenolic compounds, terpenoids, and alkaloids are some of the secondary metabolites present in cannabis. However, among a plethora of unique chemical compounds found in this plant, the most important ones are phytocannabinoi...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
ConclusionComorbidities are common at MS symptom onset and increase with MS duration. Having MS may thus contribute to accrual of comorbidities. This emphasises the importance of optimal screening for and management of comorbidities in early MS and throughout the disease course.
Source: Journal of Neurology - Category: Neurology Source Type: research
Conclusion The phenome-wide approach enabled a systematic interrogation of the comorbidity burden and highlighted clinically relevant medical conditions associated with MS severity (beyond MS-specific consequences) and defines a roadmap for comprehensive investigation of comorbidities in chronic neurologic diseases. Further prospective investigation of the bidirectional relationship between disability and comorbidities could inform the individualized patient management.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Electronic medical records, Multiple sclerosis Article Source Type: research
Abstract Neurological disorders (ND) are the central nervous system (CNS) related complications originated by enhanced oxidative stress, mitochondrial failure and overexpression of proteins like S100B. S100B is a helix-loop-helix protein with calcium-binding domain associated to various neurological disorders through activation of MAPK pathway, increased NFkB expression results in cell survival, proliferation and gene up-regulation. S100B protein plays a crucial role in Alzheimer's disease, Parkinson's disease, multiple sclerosis, Schizophrenia and epilepsy because high expression of this protein directly targets ...
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Neuropharmacol Source Type: research
AbstractFingolimod is an approved treatment for relapsing –remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, t hereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerativ...
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Epilepsy | Government | Legislation | Multiple Sclerosis | Pharmaceuticals | Politics | Science | UK Health